Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to admini
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Australian drug delivery company, Phosphagenics Limited (ASX: POH; ... million via a placement of A$16.3 million to institutional ... Asia and Australia ... plan (SPP) to be offered to existing shareholders.  The ... tranches. "This capital raising positions us strongly ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Ill., July 28, 2011 The National ... health alert to warn Americans about the serious dangers ... report NABP released today on Internet drug outlets found ... to operate out of compliance with United States pharmacy ...
... Boston Scientific Corporation,s (NYSE: BSX ) Board ... repurchase of up to $1.0 billion of its common ... under an existing share repurchase program. "This ... the Company,s long-term business prospects, earnings growth potential and ...
Cached Medicine Technology:NABP Issues Rogue Online Pharmacy Public Health Alert 2NABP Issues Rogue Online Pharmacy Public Health Alert 3NABP Issues Rogue Online Pharmacy Public Health Alert 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a ... Pavilion . When it comes to the summer concert schedule, ... 37-year-old Georgia native is one of the biggest names in country ... Bryan is currently out on his “That’s My Kind of Night” ... the tour will be making through the rest of the summer ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... R.I. -- Researchers from The Miriam Hospital ... age 65 have significantly higher rates of smoking ... mobility impairments were less likely to attempt quitting ... treatments may not be sufficient for this population. ... in advance of print in the American ...
(Date:7/11/2014)... to repair damage to the anterior cruciate ligament (ACL) -- ... could increase a young athlete,s risk for further injuries, researchers ... aged 8 to 16, who had ACL reconstruction surgery. Of ... their injury, 37 had surgery six to 12 weeks after, ... their injury. The youngsters who had surgery later had ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... ... May 15 Meet Cindy Zamirowski, a 56-year-old,breast cancer survivor who less ... stepped off the curb to raise funds for,cancer research in the 5K ... and grandma of three rallied her team of,16 angels at her side ...
... 15 Cleveland Clinic announced today that,the Cleveland ... Reserve,University is providing all its students with full ... Approaching its fifth year in existence, the Cleveland ... training of physician scientists,who are capable of furthering ...
... the Department of Urology have showed that lowering intake of ... prevent prostate cancer in mice, the first finding of its ... researchers said. , The study, which appears in the April ... fat from corn oil, which is made up primarily of ...
... Maxi-K gene therapy may be a safe and effective ... not treatable with oral therapy. Two studies presented today ... Urological Association (AUA) may give hope to these individuals. ... press conference on May 20, 2008 at 10 a.m. ...
... FL, May 20, 2008 Rising global temperatures could ... research presented today at the 103rd Annual Scientific Meeting ... linked to stone disease, particularly in warmer climates, and ... the prevalence of stone disease may increase, along with ...
... 20, 2008 Patients with metabolic syndrome disorders, including ... to develop uric-acid stones than other type of ... 103rd Annual Scientific Meeting of the American Urological ... with uric acid stones could benefit from additional ...
Cached Medicine News:Health News:After Effects: Giving Back Is Good for You 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 3Health News:Reducing intake of dietary fat prevents prostate cancer in mice 2Health News:AUA 2008: Maxi-K gene transfer may prove to be safe and effective erectile dysfunction treatment 2Health News:AUA 2008: Uric acid stones may indicate arteriosclerotic diseases 2
Inquire...
Electric Reciprocating Saw, with hand throttle. Can also be purchased without hand throttle (#1915) for use with foot pedal. (#6401-000)...
... without hand throttle, 30,000 RPM, ... medium bur guard included, long ... guards are also available. Must ... (#6401-000), can also be purchased ...
... USA 2001 Universal Battery Charger is manufactured to ... Versipower Plus and 3M MaxiDriver II Battery Packs. ... six Battery Packs simultaneously in less than 40 ... on 120 volt AC grounded electrical power. If ...
Medicine Products: